Ann S LaCasce
Overview
Explore the profile of Ann S LaCasce including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
4826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patell R, Bindal P, Freed J, Dodge L, Nagaraj G, LaCasce A, et al.
J Natl Compr Canc Netw
. 2025 Mar;
23(3):82-89.
PMID: 40073833
Background: Oncology providers often lack the confidence to make clinical recommendations about medical cannabis (MC). This study aimed to develop and evaluate the feasibility of implementing an educational curriculum on...
2.
Johnson P, Abramson J, LaCasce A, Armand P, Barnes J, Merryman R, et al.
J Natl Compr Canc Netw
. 2025 Feb;
23(3).
PMID: 39970870
Background: Aggressive non-Hodgkin lymphoma (aNHL) is more common in older adults. Although chemoimmunotherapy can yield durable remissions, it is also associated with significant toxicities. Despite this, longitudinal studies assessing patient-reported...
3.
4.
Crombie J, LaCasce A
J Clin Oncol
. 2025 Jan;
43(9):1047-1049.
PMID: 39772656
No abstract available.
5.
Gupta S, Kaunfer S, Chen K, Dias J, Vijayan A, Rajasekaran A, et al.
Blood
. 2025 Jan;
PMID: 39760780
High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are...
6.
Davids M, Ryan C, Lampson B, Ren Y, Tyekucheva S, Fernandes S, et al.
J Clin Oncol
. 2024 Dec;
43(7):788-799.
PMID: 39645236
Purpose: The AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard-of-care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wild-type ; however,...
7.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
24(12):873.
PMID: 39603773
No abstract available.
8.
Looka A, Qualls D, Matthews D, Redd R, Sakellis C, Duffy C, et al.
Blood Adv
. 2024 Nov;
9(3):455-462.
PMID: 39546746
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are anti-CD19 chimeric antigen receptor (CAR) T-cell therapies approved for relapsed and refractory large B-cell lymphoma (LBCL); however, there is currently no published...
9.
Merrill M, Cahill S, Pepprock H, Redd R, Rana H, Economy K, et al.
JCO Precis Oncol
. 2024 Sep;
8:e2400058.
PMID: 39298712
No abstract available.
10.
Zaccardelli A, Lucas F, LaCasce A, Chandraker A, Azzi J, Talbot S
Front Transplant
. 2024 Jul;
3:1339898.
PMID: 38993757
Vascularized composite allotransplantation (VCA) is an emerging field in transplant surgery. Despite overall positive outcomes, VCA confers risk for multiple complications related to the procedure and subsequent immunosuppression. Post-transplant lymphoproliferative...